AGC Biologics, a CDMO expert, has been selected by Teikoku Seiyaku Co., Ltd. to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.
AGC Biologics to Support Teikoku Seiyaku’s KTP-001
Share: